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Abstract
Choice of one method over another for MHC-II binding peptide prediction is typically based on published reports of their
estimated performance on standard benchmark datasets. We show that several standard benchmark datasets of unique
peptides used in such studies contain a substantial number of peptides that share a high degree of sequence identity with
one or more other peptide sequences in the same dataset. Thus, in a standard cross-validation setup, the test set and the
training set are likely to contain sequences that share a high degree of sequence identity with each other, leading to overly
optimistic estimates of performance. Hence, to more rigorously assess the relative performance of different prediction
methods, we explore the use of similarity-reduced datasets. We introduce three similarity-reduced MHC-II benchmark
datasets derived from MHCPEP, MHCBN, and IEDB databases. The results of our comparison of the performance of three
MHC-II binding peptide prediction methods estimated using datasets of unique peptides with that obtained using their
similarity-reduced counterparts shows that the former can be rather optimistic relative to the performance of the same
methods on similarity-reduced counterparts of the same datasets. Furthermore, our results demonstrate that conclusions
regarding the superiority of one method over another drawn on the basis of performance estimates obtained using
commonly used datasets of unique peptides are often contradicted by the observed performance of the methods on the
similarity-reduced versions of the same datasets. These results underscore the importance of using similarity-reduced
datasets in rigorously comparing the performance of alternative MHC-II peptide prediction methods.
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Introduction
T-cells epitopes are short linear peptides generated by cleavage
of antigenic proteins. The identification of T-cell epitopes in
protein sequences is important for understanding disease patho-
genesis, identifying potential autoantigens, and designing vaccines
and immune-based cancer therapies. A major step in identifying
potential T-cell epitopes involves identifying the peptides that bind
to a target major histocompatibility complex (MHC) molecule.
Because of the high cost of experimental identification of such
peptides, there is an urgent need for reliable computational
methods for predicting MHC binding peptides [1].
There are two major classes of MHC molecules: MHC class I
(MHC-I) molecules characterized by short binding peptides,
usually consisting of nine residues; and MHC class II (MHC-II)
molecules with binding peptides that range from 11 to 30 residues
in length, although shorter and longer peptide lengths are not
uncommon [2]. The binding groove of MHC-II molecules is open
at both ends, allowing peptides longer than 9-mers to bind.
However, it has been reported that a 9-mer core region is essential
for MHC-II binding [2,3]. Because the precise location of the 9-
mer core region of MHC-II binding peptides is unknown,
predicting MHC-II binding peptides tends to be more challenging
than predicting MHC-I binding peptides.
Despite the high degree of variability in the length of MHC-II
binding peptides, most existing computational methods for
predicting MHC-II binding peptides focus on identifying a 9-
mer core peptide. Computational approaches available for
predicting MHC-II binding peptides from amino acid sequences
include: (i) Motif-based methods such as methods that use a
position weight matrix (PWM) to model an ungapped multiple
sequence alignment of MHC binding peptides [4–8], and a
statistical approach based on Hidden Markov Models (HMMs)
[9,10]; (ii) Machine learning methods based on Artificial Neural
Networks (ANN) [6,11–13] and Support Vector Machines (SVMs)
[14–17]; (iii) Semi-supervised machine learning methods [18,19].
The choice of one method over another for MHC-II binding
peptide prediction requires reliable assessment of their perfor-
mance relative to each other. Such assessments usually rely on
estimates of their performance on standard benchmark datasets
(typically obtained using cross-validation). Several studies [5,15–
17,19] have reported the performance of MHC-II binding peptide
prediction methods using datasets of unique peptides. Such datasets
can in fact contain peptide sequences that share a high degree of
sequence similarity with other peptide sequences in the dataset.
Hence, several authors [6,7,10,20] have proposed methods for
eliminating redundant sequences. However, because MHC-II
peptides have lengths that vary over a broad range, similarity
reduction of MHC-II peptides is not a straightforward task [7].
Consequently, standard cross-validation based estimates of
performance obtained using such datasets are likely to be overly
optimistic because the test set is likely to contain sequences that
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share significant sequence similarity with one or more sequences in
the training set.
In order to obtain more realistic estimates of performance of
MHC-II binding peptide prediction methods, we explored several
methods for constructing similarity-reduced MHC-II datasets. We
constructed similarity-reduced MHC-II benchmark datasets, derived
from MHCPEP [21], MHCBN [22], and IEDB [23] databases,
using several approaches to reduce the degree of pair-wise
sequence similarity shared by sequences in the resulting datasets.
The similarity reduction procedures were applied separately to
binders and non-binders. Details of the similarity reduction
methods are provided in the Materials and Methods Section.
Specifically, we generated:
i. Datasets of unique peptides MHCPEP-UPDS, MHCBN-
UPDS, and IEDB-UPDS extracted from MHCPEP,
MHCBN, and IEDB, respectively.
ii. Datasets of similarity-reduced peptides, MHCPEP-SRDS1,
MHCBN-SRDS1, and IEDB-SRDS1 derived from the
corresponding UPDS datasets using a similarity reduction
procedure which ensures that no two peptides in the resulting
dataset share a 9-mer subsequence.
iii. Datasets of similarity-reduced peptides, MHCPEP-SRDS2,
MHCBN-SRDS2, and IEDB-SRDS2, extracted
MHCPEP-SRDS1, MHCBN-SRDS1, and IEDB-SRDS1
respectively by filtering the binders and non-binders in
SRDS1 such that the sequence identity between any pair of
peptides is less than 80%.
iv. Datasets of similarity-reduced peptides, MHCPEP-SRDS3,
MHCBN-SRDS3, and IEDB-SRDS3, derived from the
corresponding UPDS datasets using the similarity reduction
procedure introduced by Raghava and previously used to
construct the MHCBench dataset [20].
v. Datasets of weighted unique peptides, MHCPEP-WUPDS,
MHCBN-WUPDS, and IEDB-WUPDS, derived from the
corresponding UPDS datasets (where the weight assigned to
a peptide is inversely proportional to the number of peptides
that are similar to it).
We then used the resulting similarity-reduced benchmark datasets
to explore the effect of similarity reduction on the performance of
different MHC-II binding peptide prediction methods and, more
importantly, to rigorously compare the performance of the
different prediction methods.
Our experiments focused on two state-of-the-art methods for
training MHC-II binding peptide predictors using variable-length
MHC-II peptides and a third method that is designed to exploit
the sequence similarity between a test peptide sequence and the
peptide sequences in the training set (and is hence likely to perform
well on non similarity-reduced datasets but poorly on the similarity-
reduced datasets).
Specifically, we compared: (i) An approach [16] that maps each
variable-length peptide into a fixed-length feature vector (the so-
called composition-transition distribution or CTD) consisting of
sequence-derived structural features and physicochemical proper-
ties of the input peptide sequence; (ii) An approach [17] that uses a
local alignment (LA) kernel that defines the similarity between two
variable-length peptides as the average of all possible local
alignments between the two peptides; (iii) An approach that uses
the k-spectrum kernel [24] with k= 5.
Because neither the programs used to calculate secondary
structure and solvent accessibility of peptides used for generating
the CTD representation [16] nor the precise choices of parameters
used for training the LA kernel based classifier [17] were available
to us, we used in our experiments, our own implementations of the
corresponding methods. Hence, the results of our experiments
should not be viewed as providing direct assessment of
performance of the exact implementations of the CTD and LA
methods developed by the original authors and used in studies
reported in [16,17]. However, it is worth noting that, the broad
conclusions of our study are largely independent of the specific
machine learning methods or data transformations.
Our results demonstrate that, regardless of the similarity
reduction method employed, a substantial drop in performance
of classifiers is observed compared to their reported performance
on benchmark datasets of unique peptide sequences. Our results
also demonstrate that conclusions regarding the superiority of one
prediction method over another can be misleading when they are
based on evaluations using benchmark datasets with a high degree
of sequence similarity (e.g., the benchmark dataset of unique
peptide sequences). These results underscore the importance of
using similarity-reduced datasets in evaluating and comparing
alternative MHC-II peptide prediction methods.
Results
Limitations of the unique peptides MHC-II data
Tables 1–3 show that MHC-II datasets derived from
MHCPEP, MHCBN, and IEDB databases have a large number
of highly similar peptides: the number of peptides in the similarity-
reduced versions in the three benchmark datasets is <50% of the
original number. In each case, the estimated performance of the
Table 1. Number of binding peptides in MHCPEP benchmark
dataset.
Allele UPDS SRDS1 SRDS2 SRDS3
HLA-DQ2 113 67 32 39
HLA-DQ4 97 84 79 82
HLA-DQ7 135 73 65 75
HLA-DR1 703 336 242 278
HLA-DR2 315 148 104 134
HLA-DR3 192 81 69 73
HLA-DR4 1085 439 298 353
HLA-DR5 189 92 61 75
HLA-DR7 341 137 87 101
HLA-DR8 125 47 46 54
HLA-DR9 94 41 34 37
HLA-DR11 473 160 100 103
HLA-DR13 121 68 34 36
HLA-DR15 121 48 36 49
HLA-DR17 158 82 40 45
HLA-DR51 115 45 39 55
I-Ab 136 62 51 61
I-Ad 415 168 101 135
I-Ag7 157 62 53 81
I-Ak 254 96 67 85
I-Ed 294 188 68 76
I-Ek 334 204 64 78
UPDS refers to datasets of non-redundant peptides. The last three columns
refer to similarity-reduced datasets (see text for details).
doi:10.1371/journal.pone.0003268.t001
Binding Peptide Predictors
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prediction methods evaluated on similarity-reduced datasets is
substantially worse than that estimated using the datasets of
unique peptides. This finding is especially significant in light of the
fact that MHCPEP and MHCBN datasets have been used for
comparing alternative MHC-II peptide prediction methods in
most of the published studies [5,6,15–19,25].
For the sake of brevity, we focus discussion here on the results of
two representative examples of datasets extracted from the
MHCPEP and MHCBN benchmarks and provide the complete
set of results in the supplementary materials (Data S1).
As shown in Table 4, for the MHCPEP benchmark, we focus on
the results on the data for HLA-DR4, which has the largest
number of unique binders. On the MHCPEP-UPDS version of the
HLA-DR4 dataset, the 5-spectrum kernel outperforms the other
two prediction methods and CTD outperforms the LA kernel. We
notice a substantial drop in the observed performance of the three
prediction methods on the similarity-reduced and weighted datasets
relative to that on their UPDS counterpart.
In the case of the MHCBN benchmark, we focus on the results
on the HLA-DRB1*0301 data (Table 5) because it has been used
in a number of recent studies of MHC-II binding peptide
prediction methods [16,17,25]. Most MHCBN allele-specific
datasets are unbalanced, i.e., the numbers of binding peptides in
the datasets are larger (typically by a factor of 2 to 4) than the
corresponding numbers of non-binding peptides (see Table 2). On
such unbalanced datasets, classification accuracy can be mislead-
ing in terms of providing a reliable and useful assessment of the
performance of the classifier. A classifier that simply returns the
label of the majority class as the predicted label for each instance
to be classified can achieve a rather high accuracy; However such
Table 2. Number of binding/non-binding peptides in MHCBN
benchmark dataset.
Allele UPDS SRDS1 SRDS2 SRDS3
HLA-DR1 636/180 328/111 223/106 259/130
HLA-DR2 416/168 197/124 153/123 232/149
HLA-DR5 218/173 111/131 80/129 100/154
HLA-DRB10101 531/127 325/88 279/76 390/112
HLA-DRB10301 261/230 137/150 127/145 175/215
HLA-DRB10401 805/201 471/136 404/119 543/174
HLA-DRB10701 292/107 179/68 152/66 213/92
HLA-DRB11101 352/137 213/87 182/87 239/131
UPDS refers to datasets of non-redundant peptides. The last three columns
refer to similarity-reduced datasets (see text for details).
doi:10.1371/journal.pone.0003268.t002
Table 3. Number of binding/non-binding peptides in IEDB
benchmark dataset.
Allele UPDS SRDS1 SRDS2 SRDS3
HLA-DRB1-0101 1105/432 645/268 623/261 938/365
HLA-DRB1-0301 135/556 78/292 69/276 81/396
HLA-DRB1-0401 317/412 197/262 176/255 215/340
HLA-DRB1-0404 113/132 69/100 62/98 74/109
HLA-DRB1-0405 113/119 74/85 70/84 81/89
HLA-DRB1-0701 228/302 147/203 137/202 173/274
HLA-DRB1-0802 65/120 46/101 46/100 49/108
HLA-DRB1-1101 197/411 122/218 111/212 139/328
HLA-DRB1-1302 152/103 105/81 97/81 110/92
HLA-DRB1-1501 269/283 165/176 142/174 185/260
HLA-DRB4-0101 92/215 64/120 63/119 85/200
HLA-DRB5-0101 215/377 123/201 113/194 147/309
UPDS refers to datasets of non-redundant peptides. The last three columns
refer to similarity-reduced datasets (see text for details).
doi:10.1371/journal.pone.0003268.t003
Table 4. Performance of prediction methods on MHCPEP
HLA-DR4 unique, similarity-reduced, and weighted datasets
using 5-fold cross-validation test.
Dataset Method ACC Sn Sp CC AUC
UPDS CTD 86.59 73.36 99.82 0.759 0.906
LA 77.10 71.71 82.49 0.545 0.862
5-spectrum 90.55 81.29 99.82 0.825 0.917
SRDS1 CTD 69.93 66.06 73.80 0.400 0.723
LA 68.56 63.78 73.35 0.373 0.751
5-spectrum 70.96 43.28 98.63 0.503 0.710
SRDS2 CTD 64.77 60.40 69.13 0.296 0.692
LA 64.43 65.10 63.76 0.289 0.711
5-spectrum 56.04 33.22 78.86 0.136 0.578
SRDS3 CTD 65.01 61.47 68.56 0.301 0.695
LA 64.02 62.89 65.16 0.281 0.717
5-spectrum 68.56 38.81 98.30 0.462 0.679
WUPDS CTD 85.41 31.98 99.91 0.516 0.730
LA 79.38 22.50 94.81 0.249 0.723
5-spectrum 87.14 42.14 99.35 0.580 0.723
doi:10.1371/journal.pone.0003268.t004
Table 5. Performance of prediction methods on MHCBN HLA-
DRB1*0301 unique, similarity-reduced, and weighted datasets
using 5-fold cross-validation test.
Dataset Method ACC Sn Sp CC AUC
UPDS CTD 72.51 73.95 70.87 0.448 0.787
LA 71.89 73.56 70.00 0.436 0.795
5-spectrum 70.26 82.76 56.09 0.405 0.770
SRDS1 CTD 63.41 64.23 62.67 0.269 0.661
LA 58.54 59.85 57.33 0.172 0.617
5-spectrum 42.16 63.50 22.67 20.152 0.323
SRDS2 CTD 59.93 59.06 60.69 0.197 0.628
LA 55.88 54.33 57.24 0.116 0.563
5-spectrum 35.29 37.01 33.79 20.292 0.273
SRDS3 CTD 64.62 60.57 67.91 0.285 0.675
LA 67.18 61.14 72.09 0.334 0.736
5-spectrum 63.08 49.71 73.95 0.244 0.678
WUPDS CTD 65.27 61.04 68.88 0.300 0.678
LA 66.66 64.47 68.53 0.330 0.710
5-spectrum 59.97 58.70 61.04 0.197 0.648
doi:10.1371/journal.pone.0003268.t005
Binding Peptide Predictors
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a classifier is rather useless in reliably identifying members of the
minority class. Hence, in the case of unbalanced datasets, the
correlation coefficient (CC) or the area under the Receiver
Operating Characteristic (ROC) curve (AUC) provide more useful
measures than accuracy in assessing the performance of the
classifiers [26]. As shown in Table 5, the observed performance of
the three prediction methods on HLA-DRB1*0301 MHCBN-
UPDS version of this dataset appears to be overly optimistic
relative to that on its similarity-reduced and weighted counterparts.
Interestingly, the 5-spectrum kernel is competitive with CTD and
LA on the MHCBN-UPDS dataset, whereas its performance on
MHCBN-SRDS1 and MHCBN-SRDS2 is much worse than that
of the CTD and the LA classifiers.
Our results also demonstrate that conclusions of superior
performance of one method relative to another that are based
on estimates of performance obtained using UPDS versions of
MHC-II benchmark datasets can be misleading. For example,
from results shown in Tables 4 and 5, one might be tempted to
conclude that predictors that use the 5-spectrum kernel are
competitive with those that use CTD representation and the LA
kernel. However, the 5-spectrum kernel is outperformed by CTD
and LA on the similarity-reduced datasets. Similarly, conclusions
drawn from experiments using the UPDS datasets (Tables 4 and 5)
regarding the performance of the CTD and the LA kernel
classifiers are contradicted by the their observed performance on
the corresponding similarity-reduced datasets SRDS1 and SRDS2.
Limitations of the MHCBench benchmark data
Comparison of SRDS1, SRDS2, and SRDS3 versions of the
datasets used in this study reveals an important limitation of the
MHCBench dataset which is a widely used benchmark for
comparing MHC-II binding peptide prediction methods.
Recall that the SRDS3 versions of our datasets are derived using
the same procedure that was used in MHCBench to generate
similarity-reduced datasets. It is clear from the data summarized in
Tables 1–3 that the size of a SRDS3 version of a dataset is: often
larger than the size of its SRDS2 counterpart, and sometimes
larger than the size of its SRDS1 counterpart. Closer examination
of the peptides in SRDS3 datasets reveals that SRDS3 datasets
may contain several highly similar peptides (e.g., peptides with
more than 80% sequence similarity). This is illustrated by the
example shown in Figure 1: the two peptides in the SRDS3
version of the HLA-DRB1*0301 dataset share overall sequence
similarity of 85.71%. However, the procedure used to construct
similarity-reduced MHCBench dataset will keep both of these
peptides in the resulting dataset because the computed percent
identity (PID) between the two peptides is only 7.7%, well below
the threshold of 80% PID used to identify similar peptides in
MHCBench [20]. Thus, the similarity reduction procedure used in
MHCBench dataset (which relies on a strict gapless alignment)
may not eliminate all highly similar peptides.
The preceding observation explains why the number of peptides
in the SRDS3 versions of the datasets is usually greater than that
in SRDS1 and SRDS2 datasets (see Tables 1–3). More
importantly, because of the presence of a number of highly
similar peptides in some SRDS3 datasets, the observed perfor-
mance of the three prediction methods on the SRDS3 datasets
may be overly optimistic relative to that estimated from their
SRDS1 and SRDS2 counterparts. Because the classifier using the
5-spectrum kernel in fact relies on the degree of (gapless) match
between a sequence pattern present in one or more training
sequences and a test sequence, it benefits from the presence of a
high degree of similarity between a test sequence and one or more
training sequences in ways that the other two classifiers do not.
Consequently classifiers that use the 5-spectrum kernel can appear
to be competitive with, and perhaps even outperform those that
use the CTD representation or the LA kernel when their
performance is compared using SRDS3 datasets (and for similar
reasons, the MHCBench benchmark data).
Comparison of the CTD, LA, and the k-spectrum kernel
methods
In machine learning and bioinformatics literature, claims of
superiority of one method over another are often based on the
outcome of suitable statistical tests. Hence it is interesting to examine
the differences in the conclusions obtained when statistical tests are
used to compare the performance of prediction methods based on
the empirical estimates of their performance on the UPDS, SRDS1,
SRDS2, SRDS3, and WPDS versions of the datasets.
Several non-parametric statistical tests [27,28] have been
recently recommended for comparing different classifiers on
multiple datasets (accounting for the effects of multiple compar-
isons) [29]. In our analysis, we apply a three-step procedure
proposed by Demsˇar [29]. First, the classifiers to be compared are
ranked on the basis of their observed performance (e.g., AUC) on
each dataset. Second, the Friedman test is applied to determine
whether the measured average ranks are significantly different
from the mean rank under the null hypothesis. Third, if the null
hypothesis can be rejected at a significance level of 0.05, the
Nemenyi test is used to determine whether significant differences
exist between any given pair of classifiers.
Statistical analysis of results on the MHCPEP datasets
Tables 6–10 compare the AUC of the three prediction methods
on the five versions of the MHCPEP datasets. For each dataset, the
rank of each classifier is shown in parentheses. The last row in each
table summarizes the average AUC and rank for each classifier.
Demsˇar [29] has suggested that the average ranks by themselves
provide a reasonably fair comparison of classifiers. Interestingly, the
LA kernel has the worst rank among the three methods when the
comparison is based on the observed performance on the UPDS
datasets, whereas it has the best rank among the three methods when
Figure 1. Example of two peptides from MHCBN-SRDS3 HLA-DRB1*0301 dataset. Although the two peptides share 85.71% sequence
similarity, the computed percent identity (PID) used to define the similarity between these two peptides in MHCBench benchmark is only 7.7%.
doi:10.1371/journal.pone.0003268.g001
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the comparison is based on the similarity-reduced or the weighted
datasets. Tables 6–10 also show that the rank of the 5-spectrum
kernel is competitive with that of CTD on UPDS and SRDS3. This
observation is consistent with the presence of a number of highly
similar sequences in SRDS3 datasets.
To determine whether the differences in average ranks are
statistically significant, we applied the Friedman test [29] to the rank
data in Tables 6–10. At significance level of 0.05, the Friedman test
did not indicate a statistically significant difference between the
methods on the UPDS and WUPDS datasets. However, in the case
of the similarity-reduced datasets, the Friedman test indicated
statistically significant differences between the methods being
compared. Thus, we conclude that the three methods are
competitive with each other on the UPDS and WUPDS datasets,
and that there is at least one pair of classifiers with significant
difference in performance on the three versions of similarity-reduced
datasets. Furthermore, for each version of MHCPEP similarity-reduced
datasets, the Nemenyi test was applied to determine whether
significant differences exist between any given pair of classifiers.
Figure 2 summarizes the results of the pair-wise comparisons
performed using the Nemenyi test. We find that on the SRDS1
versions of the datasets, both the LA and the CTD methods
significantly outperform the 5-spectrum kernel and that there are no
statistically significant differences between the LA kernel and the
CTD classifier. On SRDS2 datasets, we find that, the performance
of each of the three methods is significantly different from that of the
other two methods, with the LA and the CTD methods ranked first
and second, respectively. On SRDS3 datasets, we observe that the
performance of the LA kernel is significantly better than that of the
CTD and the 5-spectrum classifiers, with no significant differences
between the CTD and the 5-spectrum classifiers.
Statistical analysis of results on the MHCBN and the IEDB
datasets
We summarize the results of applying Demsˇar’s three-step
procedure to the results obtained on the five versions of MHCBN
and IEDB datasets, respectively. In the case of the MHCBN datasets,
Tables 11–15 show the estimated AUC and rank of each classifier on
each dataset. The results of the Freidman test (at a significance level
of 0.05) applied to the results in each table did not indicate significant
differences in performance among the CTD, the LA, and the 5-
spectrum kernel classifiers on the UPDS dataset. However, the test
indicated statistically significant differences among the methods in
the case of the SRDS1, SRDS2, SRDS3, and the WUPDS datasets.
Figure 3 summarizes the results of the pair-wise comparisons using
the Nemenyi test. In the case of the SRDS1 and the SRDS2 datasets,
we find that the performance of both the LA kernel and the CTD
classifiers is significantly better than that of the 5-spectrum kernel
classifier and that there are no significant differences between the LA
kernel and the CTD classifiers. In the case of the SRDS3 datasets, we
find that the performance of the LA kernel classifier is significantly
better than that of the CTD and the 5-spectrum classifiers, and that
no significant differences exist between the CTD and the 5-spectrum
classifiers. In the case of the WUPDS datasets, we find that the LA
kernel classifier significantly outperforms the 5-spectrun kernel and
Table 6. AUC values for the three methods evaluated on
MHCPEP-UPDS datasets.
Allele 5-spectrum LA CTD
HLA-DQ2 0.908(2) 0.905(3) 0.939(1)
HLA-DQ4 0.628(3) 0.903(2) 0.934(1)
HLA-DQ7 0.856(2) 0.860(1) 0.853(3)
HLA-DR1 0.883(1) 0.872(2) 0.863(3)
HLA-DR2 0.884(1) 0.866(2) 0.829(3)
HLA-DR3 0.854(3) 0.869(1) 0.862(2)
HLA-DR4 0.917(1) 0.862(3) 0.906(2)
HLA-DR5 0.905(1) 0.864(3) 0.887(2)
HLA-DR7 0.916(1) 0.858(3) 0.904(2)
HLA-DR8 0.894(3) 0.896(2) 0.903(1)
HLA-DR9 0.836(3) 0.880(2) 0.913(1)
HLA-DR11 0.910(3) 0.938(2) 0.958(1)
HLA-DR13 0.875(3) 0.905(2) 0.920(1)
HLA-DR15 0.887(1) 0.829(3) 0.867(2)
HLA-DR17 0.907(2) 0.907(2) 0.934(1)
HLA-DR51 0.924(1) 0.891(2) 0.886(3)
I-Ab 0.865(2) 0.855(3) 0.875(1)
I-Ad 0.942(1) 0.898(3) 0.902(2)
I-Ag7 0.916(1) 0.896(2) 0.887(3)
I-Ak 0.909(1) 0.872(3) 0.881(2)
I-Ed 0.918(3) 0.921(2) 0.936(1)
I-Ek 0.934(3) 0.940(2) 0.951(1)
Average 0.885(1.91) 0.886(2.27) 0.900(1.77)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t006
Table 7. AUC values for the three methods evaluated on
MHCPEP-SRDS1 datasets.
Allele 5-spectrum LA CTD
HLA-DQ2 0.789(3) 0.852(2) 0.853(1)
HLA-DQ4 0.544(3) 0.854(2) 0.881(1)
HLA-DQ7 0.677(3) 0.799(1) 0.726(2)
HLA-DR1 0.662(3) 0.801(1) 0.744(2)
HLA-DR2 0.694(3) 0.795(1) 0.781(2)
HLA-DR3 0.603(2) 0.678(1) 0.572(3)
HLA-DR4 0.710(3) 0.751(1) 0.723(2)
HLA-DR5 0.691(3) 0.776(2) 0.784(1)
HLA-DR7 0.721(2) 0.702(3) 0.732(1)
HLA-DR8 0.552(3) 0.625(2) 0.694(1)
HLA-DR9 0.620(3) 0.746(1) 0.721(2)
HLA-DR11 0.703(3) 0.912(1) 0.890(2)
HLA-DR13 0.746(3) 0.827(2) 0.837(1)
HLA-DR15 0.711(2) 0.718(1) 0.667(3)
HLA-DR17 0.789(3) 0.806(2) 0.876(1)
HLA-DR51 0.651(2) 0.788(1) 0.603(3)
I-Ab 0.620(3) 0.705(1) 0.680(2)
I-Ad 0.787(3) 0.818(1) 0.804(2)
I-Ag7 0.718(2) 0.778(1) 0.702(3)
I-Ak 0.761(3) 0.800(1) 0.796(2)
I-Ed 0.826(3) 0.903(2) 0.932(1)
I-Ek 0.874(3) 0.913(2) 0.941(1)
Average 0.702(2.77) 0.789(1.45) 0.770(1.77)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t007
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that there are no significant differences between the LA and the
CTD and between the CTD and the 5-spectrum classifiers.
Results of Demsˇar’s statistical test applied to the IEDB datasets
are shown in Tables S46–S50 (Data S1 in supporting information)
and Figure 4. As in the case of MHCPEP and MHCBN, we see no
significant differences in the performance of different classifiers on
IEDB-UPDS datasets. However, in the case of the other datasets,
we find at least one pair of classifiers with significant differences in
performance. As shown in Figure 4, both the LA and the CTD
classifiers significantly outperform the 5-spectrum classifier on the
SRDS1 and the SRDS2 versions of the IEDB datasets. However,
no significant differences are observed between the CTD and the
5-spectrum methods on the SRDS3 and WUPDS versions of the
IEDB datasets.
Performance on the blind test set
The results summarized above underscore the importance of
similarity-reduced MHC-II datasets for obtaining a realistic estima-
tion of the classifier performance and avoiding misleading
conclusions. However, one might argue that in practice, when
developers of MHC-II binding peptide prediction methods make
an implementation of their methods publicly available (e.g., as an
online web server or as a web service), it might be better to utilize
as much of the available data as possible to train the predictor.
Hence, it is interesting to explore whether the UPDS datasets
should be preferred over the similarity-reduced counterparts to avoid
any potential loss of useful information due to the elimination of
highly similar peptides in a setting where the goal is to optimize the
predictive performance of the classifier on novel peptides. In what
follows, we attempt to answer this question using five allele-specific
blind test sets [30] to evaluate the performance of the three
prediction methods trained on the unique, similarity-reduced, and
weighted versions of the MHCBN data for the corresponding alleles.
Table 16 shows that the 5-spectrum kernel classifier consistently
performs poorly (AUC<0.5) on the allele-specific blind test sets
regardless of the version of the MHCBN dataset used for training
the classifier. This finding is consistent with the cross-validation
performance estimates obtained on the MHCBN SRDS1 and
SRDS2 datasets (see Tables 12 and 13).
Table 17 shows the performance on the blind test sets of the
CTD classifiers trained on different versions of MHCBN datasets.
Interestingly, the CTD classifiers appear to be relatively insensitive
to the choice of the specific version of the MHCBN dataset on
which they were trained, with an average AUC<0.66 in each case.
Finally, Table 18 summarizes the performance on the blind test
sets of the LA classifiers trained on the different versions of
MHCBN datasets. Interestingly, the best performance (on four out
of the five allele-specific blind test sets) is observed in the case of
the LA classifiers trained on the SRDS2 versions of the
corresponding allele-specific datasets.
In summary, our results show that MHC-II predictors trained on
the similarity reduced versions of the dataset generally outperform
those trained on the UPDS dataset. This suggests that similarity
reduction contributes to improved generalization on blind dataset.
Table 8. AUC values for the three methods evaluated on
MHCPEP-SRDS2 datasets.
Allele 5-spectrum LA CTD
HLA-DQ2 0.566(3) 0.678(1) 0.573(2)
HLA-DQ4 0.590(3) 0.954(1) 0.817(2)
HLA-DQ7 0.616(3) 0.713(1) 0.709(2)
HLA-DR1 0.562(3) 0.715(1) 0.711(2)
HLA-DR2 0.548(3) 0.633(1) 0.614(2)
HLA-DR3 0.514(3) 0.602(1) 0.572(2)
HLA-DR4 0.578(3) 0.711(1) 0.692(2)
HLA-DR5 0.583(3) 0.622(2) 0.625(1)
HLA-DR7 0.562(3) 0.622(1) 0.599(2)
HLA-DR8 0.526(3) 0.717(1) 0.680(2)
HLA-DR9 0.488(3) 0.754(1) 0.690(2)
HLA-DR11 0.528(3) 0.810(1) 0.792(2)
HLA-DR13 0.518(3) 0.827(1) 0.587(2)
HLA-DR15 0.592(3) 0.698(1) 0.689(2)
HLA-DR17 0.568(2) 0.612(1) 0.550(3)
HLA-DR51 0.578(3) 0.664(1) 0.595(2)
I-Ab 0.570(3) 0.624(2) 0.638(1)
I-Ad 0.623(2) 0.700(1) 0.618(3)
I-Ag7 0.713(2) 0.756(1) 0.632(3)
I-Ak 0.586(3) 0.664(1) 0.661(2)
I-Ed 0.645(3) 0.760(1) 0.744(2)
I-Ek 0.606(3) 0.756(1) 0.703(2)
Average 0.575(2.86) 0.709(1.09) 0.659(2.05)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t008
Table 9. AUC values for the three methods evaluated on
MHCPEP-SRDS3 datasets.
Allele 5-spectrum LA CTD
HLA-DQ2 0.663(2) 0.655(3) 0.754(1)
HLA-DQ4 0.608(3) 0.900(1) 0.900(1)
HLA-DQ7 0.699(3) 0.757(1) 0.706(2)
HLA-DR1 0.676(3) 0.747(1) 0.720(2)
HLA-DR2 0.724(2) 0.736(1) 0.686(3)
HLA-DR3 0.623(2) 0.657(1) 0.532(3)
HLA-DR4 0.679(3) 0.717(1) 0.695(2)
HLA-DR5 0.719(2) 0.723(1) 0.617(3)
HLA-DR7 0.631(2) 0.765(1) 0.613(3)
HLA-DR8 0.608(3) 0.732(1) 0.714(2)
HLA-DR9 0.520(3) 0.779(2) 0.792(1)
HLA-DR11 0.544(3) 0.854(1) 0.850(2)
HLA-DR13 0.563(3) 0.623(2) 0.630(1)
HLA-DR15 0.805(1) 0.713(2) 0.663(3)
HLA-DR17 0.629(3) 0.769(1) 0.682(2)
HLA-DR51 0.800(1) 0.780(2) 0.672(3)
I-Ab 0.606(3) 0.611(2) 0.618(1)
I-Ad 0.821(1) 0.785(2) 0.676(3)
I-Ag7 0.823(1) 0.804(2) 0.757(3)
I-Ak 0.768(1) 0.766(2) 0.691(3)
I-Ed 0.828(2) 0.852(1) 0.787(3)
I-Ek 0.714(2) 0.789(1) 0.699(3)
Average 0.684(2.23) 0.751(1.45) 0.702(2.27)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t009
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Discussion
Related work
Several previous studies have considered the importance of
similarity reduction in datasets of MHC-II peptides. MHCBench
[20] is a benchmark of eight HLA-DRB1*0401 datasets representing
a set of unique peptides (Set1), a dataset of natural peptides (Set2,
derived from Set1 by removing peptides with .75% Alanine
residues), two non-redundant datasets (Set3a and Set3b derived from
Set1 and Set2, respectively), two balanced datasets (Set4a and Set4b
derived from Set1 and Set2 by randomly selecting equal numbers of
binding and non-binding peptides), and two recent datasets of ligands
(Set5a and Set5b, derived from Set1 and Set2 by considering only the
most recently reported peptides). However, this benchmark considers
only a single MHC-II allele, namely, HLA-DR4 (B1*0401). More
importantly, as shown by our analysis of SRDS3 datasets, the
similarity reduction procedure used in MHCBench is not stringent
enough to ensure elimination of highly similar peptides.
Nielsen et al. [6] and Murugan et al. [18] trained their classifiers
using data extracted from MHCPEP and SYFPETHI databases and
evaluated the classifiers using ten test sets, from which peptides
similar to peptides in the training datasets had been removed.
Recently, Nielsen et al. [7] presented an MHC-II benchmarking
dataset for regression tasks: each peptide is labeled with a real value
indicating the binding affinity of the peptide. In this benchmark
dataset, each set of allele-specific data had been partitioned into five
subsets with minimal sequence overlap. However, neither of these
studies explicitly examined the limitations of widely used benchmark
datasets or the full implications of using MHC-II datasets of unique
peptides in evaluating alternative methods.
Mallios [31] compared three HLA-DRB1*0101 and HLA-
DRB1*0401 prediction tools using an independent test set of two
proteins. A consensus approach combining the predictions of the
three methods was shown to be superior to the three methods.
However, the significance of this result is limited by the small
dataset utilized in this study.
Two recent studies [30,32] have pointed out some of the
limitations of existing MHC-II prediction methods in identifying
potential MHC-II binding peptides. Gowthaman et al. [32] used
179 peptides derived from eight antigens and covering seven
MHC-II alleles to evaluate the performance of six commonly used
MHC-II prediction methods and concluded that none of these
methods can reliably identify potential MHC-II binding peptides.
Wang et al. [30] introduced a large benchmark dataset of
previously unpublished peptides and used it to assess the
performance of nine publicly available MHC-II binding peptide
prediction methods. Both studies showed that the predictive
performance of existing MHC-II prediction tools on independent
blind test sets is substantially worse than the performance of these
tools reported by their developers. Our work complements these
studies by providing a plausible explanation of this result.
We have shown that the previously reported similarity reduction
methods may not eliminate highly similar peptides, i.e., peptides
that share .80% sequence identity still pass the similarity test. We
have proposed a two-step similarity reduction procedure that is
much more stringent than those currently in use for similarity
reduction with MHC-II benchmark datasets. We have used the
similarity reduction method used in MHCBench, as well as our
proposed 2-stage method to derive similarity-reduced MHC-II
benchmark datasets based on peptides retrieved from MHCPEP
and MHCBN databases. Comparison of the similarity-reduced
versions of MHCPEP, MHCBN, and IEDB datasets with their
original UPDS counterparts showed that nearly 50% of the
peptides in the UPDS datasets are, in fact, highly similar.
Extensions to multi-class and multi-label prediction
problems
Our description of the proposed similarity reduction procedure
assumes a 2-class prediction problem. However, our proposed
approach can easily be adapted to multi-class prediction (wherein
an instance has associated with one of several mutually exclusive
labels). One can simply apply the similarity reduction procedure
separately to data from each class.
A more interesting setting is that of multi-label prediction
(wherein each instance is associated with a subset of a set of
candidate labels). Consider for example, the problem of predicting
promiscuous MHC binding peptides [33], where each peptide can
bind to multiple HLA molecules. Current methods for multi-label
prediction typically reduce the multi-label prediction task to a
collection of binary prediction tasks [34]. Hence, the similarity
reduction methods proposed in this paper can be directly applied
to the binary labeled datasets resulting from such a reduction.
Implications for rigorous assessment of MHC-II binding
peptide prediction methods
The results of our study show that the observed performance of
some of the methods (e.g., the CTD and the LA kernels) on
benchmark datasets of unique peptides can be rather optimistic
relative to the performance of the same methods on similarity-reduced
counterparts of the same datasets or on blind test sets. This suggests
that the performance of existing MHC-II prediction methods, when
Table 10. AUC values for the three methods evaluated on
MHCPEP-WUPDS datasets.
Allele 5-spectrum LA CTD
HLA-DQ2 0.717(3) 0.738(2) 0.772(1)
HLA-DQ4 0.543(3) 0.882(2) 0.925(1)
HLA-DQ7 0.716(3) 0.786(2) 0.812(1)
HLA-DR1 0.696(3) 0.710(1) 0.699(2)
HLA-DR2 0.682(2) 0.688(1) 0.617(3)
HLA-DR3 0.612(3) 0.678(1) 0.614(2)
HLA-DR4 0.723(2.5) 0.723(2.5) 0.730(1)
HLA-DR5 0.765(1) 0.709(3) 0.733(2)
HLA-DR7 0.714(1) 0.599(3) 0.632(2)
HLA-DR8 0.796(3) 0.810(1) 0.802(2)
HLA-DR9 0.806(2) 0.819(1) 0.738(3)
HLA-DR11 0.612(3) 0.798(2) 0.830(1)
HLA-DR13 0.620(2) 0.714(1) 0.605(3)
HLA-DR15 0.760(1) 0.627(2) 0.587(3)
HLA-DR17 0.747(2) 0.760(1) 0.679(3)
HLA-DR51 0.838(1) 0.786(2) 0.718(3)
I-Ab 0.650(2) 0.669(1) 0.636(3)
I-Ad 0.815(1) 0.740(2) 0.707(3)
I-Ag7 0.820(1) 0.797(2) 0.700(3)
I-Ak 0.778(1) 0.684(2) 0.680(3)
I-Ed 0.742(3) 0.760(2) 0.805(1)
I-Ek 0.734(3) 0.824(1) 0.805(2)
Average 0.722(2.11) 0.741(1.7) 0.719(2.18)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t010
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applied to novel peptide sequences, may turn out to be less
satisfactory than one might have been led to believe based on the
reported performance of such methods on some of the widely used
benchmark. Moreover, the conclusions based on observed perfor-
mance on datasets of unique peptides regarding the superior
performance of one method relative to another can be highly
unreliable in more realistic settings e.g., predictions of novel peptides.
These results underscore the importance of rigorous comparative
evaluation of a broad range of existing methods for MHC-II binding
peptides prediction methods using similarity-reduced datasets. We
expect that such studies are likely to show much greater room for
improvement over the state-of-the-art MHC-II prediction tools than
one might be led to believe based on reported performance on the
widely-used benchmark datasets and motivate the research commu-
nity to develop improved methods for this important task. We hope
that such comparisons will be facilitated by the availability of the
similarity-reduced versions of MHCPEP, MHCBN, and IEDB datasets
used in our experiments. These datasets (Datasets S1, S2 and S3),
Java source code implementation of the similarity reduction and
weighting procedures (Code S1), and the supplementary materials
(Data S1) have been made freely available (see Supporting
Information).
Materials and Methods
The datasets used in this study are derived from MHCPEP [21],
MHCBN [22], and IEDB [23], which are manually curated
repositories of MHC binding peptides reported in the literature.
We extracted 22 MHC-II allele datasets (each with at least 100
binders) from the MHCPEP database. Because MHCPEP contains
only MHC-II binding peptides (‘‘positive examples’’), for each allele,
we generated an equal number of non-binders (‘‘negative examples’’)
by randomly extracting protein fragments from SwissProt [35]
protein sequences such that: (i) The length distribution of negative
examples is identical to that of the positive examples; (ii) None of the
non-binding peptides appear in the set of binders.
Unlike MHCPEP, MHCBN is a database of binding and non-
binding MHC peptides. MHCBN version 4.0 has 35 MHC-II
alleles with at least 100 binders. Out of these 35 alleles, only eight
alleles have at least 100 non-binders. We extracted the MHCBN
benchmark dataset used in this study from the alleles for which at
least 100 binders and non-binders peptides are available in
MHCBN.
The Immune Epitope Database and Analysis Resource (IEDB)
[23] is a rich resource of MHC binding data curated from the
literature or submitted by immunologists. For each reported
peptide, IEDB provides qualitative (i.e., Negative or Positive) and
quantitative (i.e., IC50) measurements whenever available. We
used both qualitative and quantitative measurements for con-
structing 12 HLA binary labeled datasets as follows:
N Peptides with no reported quantitative measurements are
discarded.
N Peptides with ‘‘Positive’’ qualitative measurement and quan-
titative measurement less than 500 nM are classified as
binders.
Figure 2. Pair-wise comparisons of classifiers with the Nemenyi test applied to results on a) MHCPEP-SRDS1, b) MHCPEP-SRDS2,
and c) MHCPEP-SRDS3. Classifiers that are not significantly different (at p-value= 0.05) are connected.
doi:10.1371/journal.pone.0003268.g002
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N Peptides with ‘‘Positive’’ qualitative measurement and quan-
titative measurement greater than or equal 500 nM are
classified as non-binders.
N Peptides with ‘‘Negative’’ qualitative measurement and
quantitative measurement greater than or equal 500 nM are
classified as non-binders.
N Peptides with ‘‘Negative’’ qualitative measurement and
quantitative measurement less than 500 nM are discarded.
The reported MHC binding sites are typically identified using
truncation, substitution, or mutations in a base peptide [36].
Because different reported MHC-II binding peptides might
actually correspond to experimental manipulation of the same
MHC-II binding region using different experimental techniques or
different choices of amino acids targeted for truncation, substitu-
tion, or mutation, it is not surprising that that MHC databases
contain a significant number of highly similar peptides. Hence, we
used several similarity reduction methods to extract several
different versions of the dataset from each set of sequences.
It should be noted that the existence of highly similar peptides
belonging to the same category may result in an over-optimistic
estimation of the classifier performance. Therefore, we applied the
similarity reduction procedures separately to the set of binders and
non-binders in each dataset. The following sections describe the
similarity reduction procedures and the resulting similarity-reduced
datasets.
Table 11. AUC values for the three methods evaluated on
MHCBN-UPDS datasets.
Allele 5-spectrum LA CTD
HLA-DR1 0.747(3) 0.768(2) 0.789(1)
HLA-DR2 0.806(1) 0.771(3) 0.786(2)
HLA-DR5 0.743(3) 0.748(2) 0.752(1)
HLA-DRB10101 0.758(3) 0.799(2) 0.804(1)
HLA-DRB10301 0.770(3) 0.795(1) 0.787(2)
HLA-DRB10401 0.705(3) 0.780(1) 0.721(2)
HLA-DRB10701 0.778(2) 0.842(1) 0.732(3)
HLA-DRB11101 0.754(3) 0.874(1) 0.832(2)
Average 0.758(2.63) 0.797(1.63) 0.775(1.75)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t011
Table 12. AUC values for the three methods evaluated on
MHCBN-SRDS1 datasets.
Allele 5-spectrum LA CTD
HLA-DR1 0.545(3) 0.784(1) 0.738(2)
HLA-DR2 0.456(3) 0.707(2) 0.750(1)
HLA-DR5 0.533(3) 0.657(2) 0.692(1)
HLA-DRB10101 0.456(3) 0.690(2) 0.748(1)
HLA-DRB10301 0.323(3) 0.617(2) 0.661(1)
HLA-DRB10401 0.381(3) 0.676(1) 0.655(2)
HLA-DRB10701 0.424(3) 0.665(2) 0.748(1)
HLA-DRB11101 0.493(3) 0.776(1) 0.759(2)
Average 0.451(3.00) 0.697(1.63) 0.719(1.38)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t012
Table 13. AUC values for the three methods evaluated on
MHCBN-SRDS2 datasets.
Allele 5-spectrum LA CTD
HLA-DR1 0.448(3) 0.717(1) 0.698(2)
HLA-DR2 0.374(3) 0.665(2) 0.716(1)
HLA-DR5 0.369(3) 0.459(2) 0.588(1)
HLA-DRB10101 0.351(3) 0.705(1) 0.683(2)
HLA-DRB10301 0.273(3) 0.563(2) 0.628(1)
HLA-DRB10401 0.261(3) 0.658(1) 0.620(2)
HLA-DRB10701 0.414(3) 0.617(2) 0.696(1)
HLA-DRB11101 0.386(3) 0.705(2) 0.757(1)
Average 0.360(3.00) 0.636(1.63) 0.673(1.38)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t013
Table 14. AUC values for the three methods evaluated on
MHCBN-SRDS3 datasets.
Allele 5-spectrum LA CTD
HLA-DR1 0.685(3) 0.768(1) 0.743(2)
HLA-DR2 0.709(3) 0.741(1) 0.719(2)
HLA-DR5 0.557(3) 0.616(1) 0.608(2)
HLA-DRB10101 0.691(3) 0.819(1) 0.725(2)
HLA-DRB10301 0.678(2) 0.736(1) 0.675(3)
HLA-DRB10401 0.624(3) 0.760(1) 0.710(2)
HLA-DRB10701 0.737(2) 0.794(1) 0.671(3)
HLA-DRB11101 0.755(3) 0.816(1) 0.775(2)
Average 0.680(2.75) 0.756(1.00) 0.703(2.25)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t014
Table 15. AUC values for the three methods evaluated on
MHCBN-WUPDS datasets.
Allele 5-spectrum LA CTD
HLA-DR1 0.655(3) 0.747(1) 0.732(2)
HLA-DR2 0.636(3) 0.717(2) 0.740(1)
HLA-DR5 0.518(3) 0.594(1) 0.543(2)
HLA-DRB10101 0.535(3) 0.672(1) 0.666(2)
HLA-DRB10301 0.648(3) 0.710(1) 0.678(2)
HLA-DRB10401 0.536(3) 0.757(1) 0.701(2)
HLA-DRB10701 0.667(3) 0.724(1) 0.702(2)
HLA-DRB11101 0.676(3) 0.820(1) 0.789(2)
Average 0.609(3) 0.718(1.13) 0.694(1.88)
For each dataset, the rank of each classifier is shown in parentheses.
doi:10.1371/journal.pone.0003268.t015
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Similarity reduction procedures
An example of two different types of similar peptides that
frequently occur in MHC peptides databases is shown in Figure 5.
In type I, two peptides differ from each other in terms of only one
or two amino acids (see Figure 5A). Such highly similar peptides
are likely to have come from different mutation experiments
targeting different sites of the same MHC-II binding peptide. For
example, Garcia et al. [37] report an HLA-DRB1*0401 binding
peptide (WGENDTDVFVLNNTR) and 12 additional binding
peptides derived from that peptide by replacing one of the amino
acid in (WGENDTDVFVLNNTR) sequence with Glycine and
experimentally determining the binding affinity of the new
peptide. In type II, we find that a shorter peptide in one allele
dataset corresponds to a sub-sequence of a longer one that is also
in the allele dataset (see Figure 5B).
Standard approaches to identifying similar peptide sequences rely
on the use of a sequence similarity threshold. Sequences that are
within a certain predetermined similarity threshold relative to a
target sequence are eliminated from the dataset. However, the use of
such a simple approach to obtaining a similarity reduced dataset is
complicated by the high degree of variability in the length of MHC-
II peptides. Using a single fixed similarity cutoff value (e.g. 80%)
might not be effective in eliminating type II similar peptides. On the
other hand, an attempt to eliminate one of the two such similar
sequences by using of a more stringent similarity threshold could
result in elimination of most of the dataset.
To address this problem, we used a two-step similarity reduction
procedure to eliminate similar peptides of types I and II:
N Step 1 eliminates similar peptides based on a criterion
proposed by Nielsen et al. [7]. Two peptides are considered
similar if they share a 9-mer subsequence. This step will
eliminate all similar peptides of type II but is not guaranteed to
remove all similar peptides of Type I. For example, this
method will not eliminate one of the two peptides in Figure 5A
although they share 84.6% sequence similarity.
N Step 2 filters the dataset using an 80% similarity threshold to
eliminate any sequence that has a similarity of 80% or greater
with one or more sequences in the dataset.
In addition, we also used a procedure proposed by Raghava [20]
for similarity reduction of MHCBench benchmark datasets. Briefly,
given two peptides p1 and p2 of lengths l1 and l2 such that l1#l2, we
compare p1 with each l1-length subpeptide in p2. If the percent
Figure 3. Pair-wise comparisons of classifiers with the Nemenyi test applied to results on a) MHCBN-SRDS1, b) MHCBN-SRDS2, c)
MHCBN-SRDS3, and d) MHCBN-WUPDS. Classifiers that are not significantly different (at p-value= 0.05) are connected.
doi:10.1371/journal.pone.0003268.g003
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identity (PID) between p1 and any subpeptide in p2 is greater than
80%, then the two peptides are deemed to be similar. For example,
to compute the PID between (ACDEFGHIKLMNPQRST) and
(DEFGGIKLMN), we compare (DEFGGIKLMN) with (ACDEF-
GHIKL), (CDEFGHIKLM), …, (IKLMNPQRST). The PID
between (DEFGGIKLMN) and (DEFGHIKLMN) is 90% since
nine out of 10 residues are identical.
Finally, we explored a method for assigning weights to similar
peptides as opposed to eliminating similar peptides from the
dataset. Specifically, the peptides within the binders category that
are similar to each other (i.e., share a 9-mer subsequence or have
Figure 4. Pair-wise comparisons of classifiers with the Nemenyi test applied to results on a) IEDB-SRDS1, b) IEDB-SRDS2, c) IEDB-
SRDS3, and d) IEDB-WUPDS. Classifiers that are not significantly different (at p-value= 0.05) are connected.
doi:10.1371/journal.pone.0003268.g004
Table 16. AUC values for 5-spectrum based classifiers trained
using MHCBN- UPDS, SRDS1, SRDS2, SRDS3, and WUPDS
datasets and evaluated on the blind test sets of Wang et al.
[30].
Allele UPDS SRDS1 SRDS2 SRDS3 WUPDS
HLA-DRB1-0101 0.505 0.503 0.504 0.506 0.505
HLA-DRB1-0301 0.518 0.515 0.515 0.516 0.518
HLA-DRB1-0401 0.504 0.500 0.500 0.501 0.487
HLA-DRB1-0701 0.500 0.500 0.500 0.500 0.496
HLA-DRB1-1101 0.500 0.500 0.500 0.500 0.496
Average 0.505 0.504 0.504 0.505 0.500
doi:10.1371/journal.pone.0003268.t016
Table 17. AUC values for CTD classifiers trained using
MHCBN- UPDS, SRDS1, SRDS2, SRDS3, and WUPDS datasets
and evaluated on the blind test sets of Wang et al. [30].
Allele UPDS SRDS1 SRDS2 SRDS3 WUPDS
HLA-DRB1-0101 0.689 0.707 0.684 0.714 0.629
HLA-DRB1-0301 0.595 0.589 0.597 0.596 0.585
HLA-DRB1-0401 0.605 0.584 0.611 0.633 0.601
HLA-DRB1-0701 0.675 0.711 0.699 0.684 0.694
HLA-DRB1-1101 0.732 0.701 0.719 0.713 0.735
Average 0.659 0.658 0.662 0.668 0.649
doi:10.1371/journal.pone.0003268.t017
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sequence similarity of 80% or greater) are clustered together. Each
peptide that is assigned to a cluster is similar to at least one other
peptide within the cluster, and no two similar peptides are assigned
to different clusters. Each peptide in a cluster is assigned a weight
of 1=n, where n is the number of peptides assigned to the cluster.
The process is repeated with peptides in the non-binders category.
The result is a dataset of weighted instances.
Thus, from each MHC-II benchmark dataset, we generated five
versions summarized below:
N Three datasets of unique peptides, MHCPEP-UPDS, MHCBN-
UPDS, and IEDB-UPDS extracted from MHCPEP,
MHCBN, and IEDB, respectively after eliminating short
peptides consisting of fewer than 9 residues, unnatural
peptides, peptides with greater than 75% Alanine residues,
and duplicated peptides.
N Three datasets of similarity-reduced peptides, MHCPEP-SRDS1,
MHCBN-SRDS1, and IEDB-SRDS1 derived from the
corresponding UPDS datasets described above using only step
1 of the two-step similarity reduction procedure described
above which ensures that no two peptides in the resulting
datasets of binders or non binders share a 9-mer subsequence.
N Three datasets of similarity-reduced peptides, MHCPEP-SRDS2,
MHCBN-SRDS2, and IEDB-SRDS2, extracted MHCPEP-
SRDS1, MHCBN-SRDS1, and IEDB-SRDS1 respectively by
filtering the binders and non-binders in SRDS1 such that the
sequence identity between any pair of peptides in the binders
category or in the non-binders category is less than 80%.
N Three datasets of similarity-reduced peptides, MHCPEP-SRDS3,
MHCBN-SRDS3, and IEDB-SRDS3, derived from the
corresponding UPDS datasets by applying the similarity
reduction procedure introduced by Raghava which has been
used to construct the MHCBench dataset [20].
N Three weighted unique peptide datasets, MHCPEP-WUPDS,
MHCBN-WUPDS, and IEDB-WUPDS, derived from the
corresponding UPDS datasets by applying the peptide
weighting method described above.
The procedure used to generate the five different versions of each
allele-specific dataset using the different similarity reduction methods
and the peptide weighting method described above is shown in
Figure 6. Note that UPDS can contain similar peptides of both types
I and II; SRDS1 can contain similar peptides of type I; SRDS2 is free
from both type I and type II similar peptides; SRDS3 simulates
similarity-reduced datasets using the method employed with
MHCBench; WUPDS is a weighted version of the UPDS dataset
where similar peptides are grouped into disjoint clusters and the
weight of each peptide is set to one over the size of its cluster.
Summary of the datasets
Datasets derived from MHCPEP. Table 1 summarizes the
number of binders in each unique peptides dataset, MHCPEP-
UPDS, and the corresponding three similarity-reduced datasets,
MHCPEP-SRDS1, MHCPEP-SRDS2, and MHCPEP-SRDS3.
Note that on average, the number of binders in the similarity-reduced
datasets, MHCPEP-SRDS1, MHCPEP-SRDS2, and MHCPEP-
SRDS3, is reduced to 48%, 33%, and 39%, respectively, of the
number of binders in MHCPEP-UPDS datasets.
Datasets derived from MHCBN. Table 2 summarizes the
number of binders and non-binders in MHCBN-UPDS, MHCBN-
SRDS1, MHCBN-SRDS2 and MHCBN-SRDS3 datasets derived
for each of the eight MHCBN alleles satisfying our selection criteria.
Note that the average number of binders in similarity-reduced datasets,
MHCBN-SRDS1, MHCBN-SRDS2, and MHCBN-SRDS3, is
reduced to 55.48%, 45.46%, and 61.39%, respectively, of the
number of binders in MHCBN-UPDS datasets. Similarly, the
average number of non-binders in similarity-reduced datasets,
MHCBN-SRDS1, MHCBN-SRDS2, and MHCBN-SRDS3, is
reduced to 67.55%, 64.24%, and 87.47%, respectively, of the
number of non-binders in MHCBN-UPDS datasets.
Datasets derived from IEDB. Table 3 summarizes the
number of binders and non-binders in IEDB-UPDS, IEDB-
SRDS1, IEDB-SRDS2, and IEDB-SRDS3 datasets derived for 12
HLA alleles. We observed that the average number of binders in
similarity-reduced datasets, IEDB-SRDS1, IEDB-SRDS2, and IEDB-
SRDS3, is reduced to 51.17%, 47.66%, and 63.5%, respectively, of
the number of binders in MHCBN-UPDS datasets. Similarly, the
average number of non-binders in similarity-reduced datasets, IEDB-
SRDS1, IEDB-SRDS2, and IEDB-SRDS3, is reduced to 60.86%,
59.38%, and 82.9%, respectively, of the number of non-binders in
MHCBN-UPDS datasets.
Independent blind set
Recently, Wang et al. [30] introduced a comprehensive dataset
of previously unpublished MHC-II peptide binding affinities and
utilized it to assessing the performance of nine publicly available
MHC-II prediction methods. The dataset covers 14 HLA alleles
Table 18. AUC values for LA classifiers trained using MHCBN-
UPDS, SRDS1, SRDS2, SRDS3, and WUPDS datasets and
evaluated on the blind test sets of Wang et al. [30].
Allele UPDS SRDS1 SRDS2 SRDS3 WUPDS
HLA-DRB1-0101 0.675 0.650 0.756 0.736 0.703
HLA-DRB1-0301 0.604 0.647 0.651 0.637 0.604
HLA-DRB1-0401 0.554 0.548 0.610 0.595 0.573
HLA-DRB1-0701 0.627 0.692 0.692 0.677 0.627
HLA-DRB1-1101 0.775 0.722 0.701 0.730 0.775
Average 0.647 0.652 0.682 0.675 0.656
doi:10.1371/journal.pone.0003268.t018
Figure 5. Two types of similar peptides that frequently appear in MHC databases.
doi:10.1371/journal.pone.0003268.g005
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and two Mouse alleles. Out of the 14 HLA allele-specific datasets,
five datasets are used in our experiments as independent blind test
data to evaluate the performance of the classifiers trained using the
corresponding MHCBN allele-specific datasets. Table 19 shows
the number of test peptides in each allele-specific dataset and the
number of binders and non-binders obtained using an IC50 cutoff
of 500 nM employed to categorize peptides into binders and non-
binders [7].
Prediction methods
Our experiments focused on two approaches for training MHC-
II binding peptide predictors from variable-length MHC-II
peptides have been recently proposed in [16,17] and a method
based on k-spectrum kernel [24] that is designed to rely on the
presence of high degree of sequence similarity between training
and test peptides (and hence is expected to perform well on
redundant datasets but poorly on similarity-reduced datasets). We
Eliminate similar peptides 
using the procedure used 
with MHCBench dataset. 
Apply weighting method 
described in the text. 
Eliminate peptides that 
share 9-mer subsequence. 
     UPDS
Remove short, unnatural, 
and duplicated peptides. 
     SRDS3      SRDS1     WUPDS 
Eliminate peptides that 
share 9-mer subsequence. 
     SRDS2
Allele-specific set of peptides retrieved 
from MHCPEP, MHCBN, or IEDB 
databases. 
Figure 6. An overview of the process used for generating five different versions of each allele dataset using the different similarity-
reduction methods described in the text.
doi:10.1371/journal.pone.0003268.g006
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implemented the three methods in java using Weka machine
learning workbench [38]. Brief descriptions of each of the three
prediction methods are included below.
Composition-Transition-Distribution (CTD)
The basic idea of this approach is to map each variable-length
peptide into a fixed-length feature vector such that standard
machine learning algorithms are applicable. This method was used
and explained in details in [16,39]. 21 features are extracted from
each peptide sequence as follows:
N First, each peptide sequence p is mapped into a string sp
defined over an alphabet of three symbols, {1,2,3}. The
mapping is performed by grouping amino acids into three
groups using a physico-chemical property of amino acids (see
Table 20). For example the peptide (AIRHIPRRIR) is mapped
into (2312321131) using the hydrophobicity division of amino
acids into three groups (see Table 20).
N Second, for each peptide string sp, three descriptors are derived
as follows:
# Composition (C): three features representing the percent
frequency of the symbols, {1, 2, 3}, in the mapped peptide
sequence.
# Transition (T): three features representing the percent
frequency of i followed by j or j followed by i, for i, jM{1,2,3}.
# Distribution (D): five features per symbol representing the
fractions of the entire sequence where the first, 25, 50, 75,
and 100% of the candidate symbol are contained in sp. A
total of 15 features are derived from each peptide.
Table 20 shows division of the 20 amino acids into three groups
based on hydrophobicity, polarizability, polarity, and Van der
Waal’s volume properties. Using these four properties, we derived
84 CTD features from each peptide sequence. In our experiments,
we trained SVM classifiers using RBF kernel and peptide
sequences represented using their amino acid sequence composi-
tion (20 features) and CTD descriptors (84 features).
Local alignment (LA) kernel
Local alignment (LA) kernel [40] is a string kernel designed for
biological sequence classification problems. The LA kernel
measures the similarity between two sequences by adding up
the scores obtained from local alignments with gaps of the
sequences. This kernel has several parameters: the gap opening
and extension penalty parameters d and e, the amino acid
mutation matrix s, and the factor b which controls the influence
of suboptimal alignments in the kernel value. Saigo et al. [40]
used the BLOSUM62 substitution matrix, gap opening and
extending parameters equal 11 and 1, respectively, and b ranges
from 0.2 to 0.5. In our experiments, we tried a range of values
for gap opening/extension and b parameters and got the best
performance out of LA kernel using BLOSUM62 substitution
matrix, gap opening and extending parameters equal 10 and 1,
respectively, and b= 0.5. Detailed formulation of the LA kernel
and a dynamic programming implementation of the kernel are
provided in [40].
k-spectrum kernel
Intuitively, a k-spectrum kernel [24] captures a simple notion of
string similarity: two strings are deemed similar (i.e., have a high k-
spectrum kernel value) if they share many of the same k-mer
substrings. We used the k-spectrum with relatively large k value,
k= 5. As noted earlier, the choice of a relatively large value for k
was motivated by the desire to construct a predictor that is
expected to perform well in settings where the peptides in the test
set share significant similarity with one or more peptides in the
training set.
Performance evaluation
The prediction accuracy (ACC), sensitivity (Sn), specificity (Sp),
and correlation coefficient (CC) are often used to evaluate
prediction algorithms [26]. The CC measure has a value in the
range from 21 to +1 and the closer the value to +1, the better the
predictor. The Sn and Sp summarize the accuracies of the positive
and negative predictions respectively. ACC, Sn, Sp, and CC are
defined as follows:
ACC~
TPzTN
TPzFPzTNzFN
Sn~
TP
TPzFN
and Sp~
TN
TNzFP
CC~
TP|TNð Þ{ FP|FNð Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TNzFNð Þ TNzFPð Þ TPzFNð Þ TPzFPð Þp
where TP, FP, TN, and FN are the numbers of true positives, false
positives, true negatives, and false negatives respectively.
Although these metrics are widely used to assess the perfor-
mance of machine learning methods, they all suffer from an
important limitation of being threshold-dependent. Threshold-
dependent metrics describe the classifier performance at a specific
threshold value. It is often possible to increase the number of true
positives (equivalently, the sensitivity) of the classifier at the
expense of an increase in false positives (equivalently, the false
alarm rate). The ROC (Receiver Operating Characteristic) curve
shows the performance of the classifier over all possible thresholds.
The ROC curve is obtained by plotting the true positive rate as a
Table 19. Five allele-specific blind test set obtained [30].
Allele peptides binders non-binders
HLA-DRB1-0101 3882 2579 1303
HLA-DRB1-0301 502 209 293
HLA-DRB1-0401 512 286 226
HLA-DRB1-0701 505 358 147
HLA-DRB1-1101 520 317 203
Peptides are categorized into binders and non-binders using an IC50 cutoff
500 nM.
doi:10.1371/journal.pone.0003268.t019
Table 20. Categorization of amino acids into three groups for
a number of physicochemical properties [42].
Property Group 1 Group 2 Group 3
Hydrophobicity RKEDQN GASTPHY CVLIMFW
Polarizability GASCTPD NVEQIL MHKFRYW
Polarity LIFWCMVY PATGS HQRKNED
Van der Waal’s volume GASDT CPNVEQIL KMHFRYW
doi:10.1371/journal.pone.0003268.t020
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function of the false positive rate or, equivalently, sensitivity versus
(1-specificity) as the discrimination threshold of the binary classifier
is varied. Each point on the ROC curve describes the classifier at a
certain threshold value and, hence, a particular choice of tradeoff
between true positive rate and false negative rate. The area under
ROC curve (AUC) is a useful summary statistic for comparing two
ROC curves. The AUC is defined as the probability that a
randomly chosen positive example will be ranked higher than a
randomly chosen negative example. An ideal classifier will have an
AUC = 1, while a classifier performs no better than random will
have an AUC = 0.5, any classifier performing better than random
will have an AUC value that lies between these two extremes.
Implementation and SVM parameter optimization
We used the Weka machine learning workbench [38] for
implementing the spectrum, and LA kernels (RBF kernel is already
implemented in Weka). For the SVM classifier, we used the weka
implementation of the SMO algorithm [41]. For k-spectrum and
LA kernels, the default value of the cost parameter, C= 1, was used
for the SMO classifier. For the RBF kernel, we found that tuning
the SMO cost parameter C and the RBF kernel parameter c is
necessary to obtain satisfactory performance. We tuned these
parameters using a two dimensional grid search over the range
C= 225,223,…,23, c= 2215,2213,…,23.
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